BioCentury | Apr 17, 2021
Deals

As German translational science begins to bloom, Evotec, BMS launch incubator in Rhine-Main-Neckar region

An improving environment for translational science in Germany has prompted Evotec to launch its latest incubator in the country. This week Evotec SE (Xetra:EVT) announced that it has partnered with Bristol Myers Squibb Co. (NYSE:BMY)...
BioCentury | Apr 14, 2021
Management Tracks

Management shuffle at Novavax; plus Skyhawk, Kyverna, Gemini and more

Greg Covino will step down as CFO and become executive adviser to Novavax Inc. (NASDAQ:NVAX). The vaccine developer hired Troy Morgan as SVP and chief compliance officer and promoted Gale Smith to SVP of discovery...
BioCentury | Apr 9, 2021
Translation in Brief

Two ways to reverse CAR T cell exhaustion; plus a ligand and its receptor in a single vector, Cleave, Amazentis and Cello

A Stanford University team led by Crystal Mackall, co-founder of Lyell Immunopharma Inc. and Obsidian Therapeutics Inc., described in Science two ways to prevent or reverse CAR T cell exhaustion. The first is based on a...
BioCentury | Apr 8, 2021
Finance

With $95M second fund and incubator, Japan-focused Remiges helps start-ups take flight

Cross-border firm Remiges Ventures will deploy its $95 million second fund to launch start-ups out of Japanese academia and invest in syndicated series A rounds, with a newly launched incubator to help...
BioCentury | Apr 7, 2021
Management Tracks

Takeda’s Koo to lead Overland-ADC joint venture; plus Precision, Amryt, Bridge, Opthea and Cogent

Eric Koo will become CEO of Overland ADCT BioPharma (CY) Ltd., the joint venture between Overland Pharmaceuticals and ADC Therapeutics S.A. (NYSE:ADCT) that launched in December. The JV is developing ADC Therapeutics’ loncastuximab tesirine, a pyrrolobenzodiazepine (PBD) dimer-linked...
BioCentury | Apr 3, 2021
Management Tracks

Biotech CEOs in China: a broadening talent pool

Growth in China’s biotech sector has driven up demand for executives who can run companies with innovative therapies that can compete on a global stage. BioCentury’s analysis shows that while MNCs remain the primary breeding...
BioCentury | Apr 3, 2021
Deals

April 2 Quick Takes: Agios begins share buybacks upon closing Servier deal, plus Royalty-GSK, Gracell-Lonza, Alloy, Eloxx-Zikani and Angelini-Ovid

Upon completing the sale of its cancer business to Servier for $1.8 billion up front and up to $200 million in milestones, Agios Therapeutics Inc. (NASDAQ:AGIO) announced plans to repurchase 7.1 million shares, or $344.5...
BioCentury | Apr 2, 2021
Management Tracks

BeiGene unveils new CFO; plus Precigen, Alphamab, Flagship, Melinta, Immunome and more

BeiGene Ltd. (NASDAQ:BGNE; HKEX:6160) promoted SVP Julia Wang to CFO, effective June 30. Wang, who joined BeiGene last June, has held leadership roles in finance at Alexion Pharmaceuticals Inc. (NASDAQ:ALXN), Johnson & Johnson (NYSE:JNJ) and...
BioCentury | Apr 1, 2021
Management Tracks

Remembering Gilead’s John Martin, whose therapies saved ‘millions’

John Martin, the visionary leader who transformed Gilead from a fledgling antisense company into an antiviral company whose drugs turned HIV into a manageable condition and cured HCV, passed away Tuesday....
BioCentury | Mar 27, 2021
Regulation

FDA approval solidifies bluebird’s anti-BCMA CAR T as ‘cornerstone’ of BMS’s multiple myeloma portfolio

FDA’s approval late Friday of Abecma idecabtagene vicleucel marks the second CAR T cell therapy BMS will bring to market as it continues to fill out its cancer portfolio ahead of revenue losses from...
Items per page:
1 - 10 of 6319